Altimmune is being questioned about the methods used for Lean Mass data, specifically regarding baseline measurements and the difference between the initial 25.5% value and the later 21.9% value. The lack of data associated with the placebo group is also a concern. Meanwhile, Eli Lilly stock (LLY) is struggling and some investors are liquidating their positions. The company recently announced FDA approval of Omvoh for Crohn's disease. The discussion also touches on the effectiveness of GLP1/GIP activation for weight loss and the lack of breakthroughs in oncology compared to Kytruda/PD1 abs.

LLY stock price is 788.47. LLY 52 Week low is None. LLY 52 Week high is None. LLY 200 day moving average is 834.64. It is currently trading below 200 day moving average. LLY 50 day moving average is 778.74 which is below(bullish) the current price. RSI (relative strength index) of LLY is 58.724 which is below (bearish) 70. Chaikin money flow (20 day) of LLY is 0.142 which is above (bullish) 0.